SCHEMBL2066554

SCHEMBL2066554

c1ccc(-c2onnc2-c2cccs2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.42
▸ KDM4E B2RXH2 6/20 0.42
▸ HPGD P15428 5/20 0.42
▸ CYP2C9 P11712 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ PPARG P37231 2/20 0.42
▸ NCOA2 Q15596 2/20 0.42
▸ NCOA1 Q15788 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ ADORA2A P29274 3/20 0.41
▸ ADORA1 P30542 2/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ RPS6KB2 Q9UBS0 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40
▸ CYP2E1 P05181 1/20 0.40
▸ CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066557 0.87 KDM4E (0.45) ALDH1A1KDM4EHPGDCYP2C9MAPT
SCHEMBL1175088 0.78 NR4A2 (0.44) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL186399 0.76 NR4A2 (0.42) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL2200421 0.72 GPR55 (0.42) ALDH1A1HPGDMAPTCYP2A6RAB9A
SCHEMBL2064327 0.71 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDCYP2C9MAPT
SCHEMBL29154651 0.71 MAPK13 (0.60) ALDH1A1KDM4EHPGDCYP2C9MAPT
SCHEMBL2065046 0.70 DPP4 (0.40) ALDH1A1KDM4EHPGDCYP2C9MAPT
SCHEMBL2064775 0.70 LTA4H (0.45) ALDH1A1KDM4EHPGDCYP2C9MAPT
Diphenylether SCHEMBL8651099 0.69 LTA4H (0.43) ALDH1A1MAPTMEN1KMT2AADORA2A
SCHEMBL28691779 0.69 KMT2A (0.50) MAPTMEN1KMT2AADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222667-B1 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2013-02-20 — — EP disclosed
US-8148410-B2 Thiophene derivatives as agonists of S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-03 — — US disclosed
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD. (CH) 2010-10-14 — — US disclosed
EP-2222667-A2 NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 Actelion Pharmaceuticals Ltd. (CH) 2010-09-01 — — EP disclosed
WO-2009074950-A2 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 ACTELION PHARMACEUTICALS LTD (CH) 2009-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261702-A1 THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 S1PR1, S1PR3, S1PR5 ALDH1A1 1141/4885KDM4E 1738/4885HPGD 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback